CoChat

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

Open access
Alamo, Patricia, Gallardo, Alberto, Di Nicolantonio, Federica, Pavón, Miguel Angel, Casanova, Isolda, Trias, Manuel, Mangues, María Antonia, Lopez‐Pousa, Antonio, Villaverde, Antonio, Vázquez, Esther, Bardelli, Alberto, Céspedes, María Virtudes, Mangues, Ramón · 2015 · The FASEB Journal
Cited by 50

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V (Kirsten rat sarcoma viral oncogene homolog with valine mutation at codon 12) and KRas G13D (Kirsten rat sarcoma viral oncogene homolog with aspartic mutation at codon 13) oncogenes in an orthotopic colorectal cancer (CRC) model. Following subcutaneous preconditioning, recombinant clones of the SW48 CRC cell line [Kras wild‐type (Kras WT)] expressing the KRas G12V or KRas G13D allele were micro‐injected in the mouse cecum. The percentage of animals developing lymph node metastasis was higher in KRas G12V than in KRas G13D mice. Microscopic, macroscopic, and visible lymphatic foci were 1.5‐ to 3.0‐fold larger in KRas G12V than in KRas G13D mice ( P < 0.05). In the lung, only microfoci were developed in both groups. KRas G12V primary tumors had lower apoptosis (7.0 ±1.2 vs . 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs . 0.6 ± 0.1, P = 0.04), and a higher percentage of C‐X‐C chemokine receptor type 4 (CXCR4)‐overexpressing intravasated tumor emboli (49.8 ± 9.4% vs . 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors. KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine‐1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression. The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing (his oncogene.—Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., Mangues, R. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB J . 29, 464‐476 (2015). www.fasebj.org

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.14-262303

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 50

Metadata

Authors
Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., & Mangues, R.
Venue
The FASEB Journal
Publisher
Wiley
Published
2014-10-30
Volume
29
Issue
2
Pages
464-476
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2012424523
Cited by
50
References
3
FWCI
1.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. https://app.cochat.ai/papers/10.1096/fj.14-262303
The paper
Alamo, P., Gallardo, A., Di Nicolantonio, F., Pavón, M. A., Casanova, I., Trias, M., Mangues, M. A., Lopez‐Pousa, A., Villaverde, A., Vázquez, E., Bardelli, A., Céspedes, M. V., & Mangues, R. (2015). Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. The FASEB Journal. https://doi.org/10.1096/fj.14-262303

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.